The National Institute for Health and Care Excellence (NICE) has maintained its decision not to recommend two treatments for Alzheimer’s disease on the NHS, after concluding that they still do not ...

The Alzheimer’s Association has launched a new, free app to help those in the early stages of the disease and their loved ...

NICE has once again rejected new drugs for early Alzheimer’s disease because the costs are too great to justify the small ...

While many are aware of memory problems as a sign of dementia, there's another early symptom of the disease to be mindful of.

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to ...

Explore key strategies for managing dementia confusion and Alzheimer’s. Learn about recognizing signs, using the Confusion Assessment Method, and adapting daily routines for better care of affected in ...

Researchers in Korea have found new substances that are effective in restoring memory and suppressing dementia. A joint ...

The National Institute for Health and Care Excellence is standing by its earlier decision to turn down donanemab and ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...

NICE published final draft guidance on donanemab and final draft guidance on lecanemab at 00:01 UK time on Thursday 19th June. Prof Charles Marshall: I have received personal fees from Lilly, Eisai ...